Outcomes of Fontan Patients Undergoing Combined Heart - Liver Transplantation in Pediatric Hospitals Across the U.S.

Why This Exists

The Fontan circulation was never meant to last a lifetime 0:11. Designed as palliation for single-ventricle congenital heart disease, it routes systemic venous return directly to the pulmonary arteries without a subpulmonary ventricle 0:11. The trade-off for survival is chronically elevated central venous pressure transmitted directly to the liver 0:11. Over decades, this produces congestive hepatopathy, fibrosis, and eventually cirrhosis 0:11. As more Fontan patients are surviving into adolescence and adulthood 0:11, liver disease is becoming a rising issue 0:11, and combined heart-liver transplantation is happening more often 0:11. This is not a rare complication anymore; it is an expected late sequela in a growing population 0:11 0:11.

The Core Problem

Fontan patients who reach end-stage heart failure face a decision tree that did not exist a generation ago 0:11. If the liver is cirrhotic — and imaging, biopsy, or laboratory markers suggest it often is by the second or third decade — should the transplant include both organs? The question matters because dual-organ transplantation is higher risk, consumes two scarce grafts, and commits the patient to lifelong immunosuppression for both 0:11. But leaving a cirrhotic liver in place after heart transplant invites portal hypertension, variceal bleeding, hepatocellular carcinoma, and graft failure from hepatic dysfunction 0:11. The clinical problem is determining when liver disease has crossed the threshold where combined transplantation is justified, and whether outcomes support that decision 0:11 0:41.

How the Approach Works

This study examined children and young adults undergoing combined heart-liver transplant at hospitals across the US in the last few years 0:21. Many of the patients had hypoplastic left heart syndrome 0:28 — the most complex single-ventricle anatomy, typically requiring three staged palliations before reaching Fontan physiology 0:28. These are not straightforward cases 0:21 0:28. The technical challenge is substantial: the liver is often enlarged, friable, and adherent from prior sternotomies 0:11. Coagulopathy from hepatic synthetic dysfunction complicates hemostasis 0:11. The heart transplant must be timed to the liver procurement, and both organs must function immediately in a patient whose physiology has been abnormal since birth 0:11 0:21.

Despite that complexity, about 85% of patients survived at 1 year 0:36, and long-term outcomes were excellent 0:36. More striking, three-year survival was basically identical to patients who received heart transplant alone 0:41. This is the finding that changes the conversation 0:41. If combined heart-liver transplant carried substantially worse outcomes than heart-only transplant, the threshold for proceeding would be high — reserved for overt cirrhosis with decompensation. But equivalent survival suggests the liver disease, once advanced enough to warrant transplantation, does not add prohibitive risk when addressed definitively 0:41.

What Remains Uncertain

The discussion does not specify how "advanced liver disease" was defined in this cohort, and that is the question every referring cardiologist needs answered. Was the threshold biopsy-proven cirrhosis? A hepatic venous pressure gradient above a certain value? Imaging findings of nodularity and portal hypertension? Laboratory markers like MELD score or platelet count? The absence of explicit criteria means clinicians are left inferring from institutional practice patterns, which vary widely. Some centers list Fontan patients for combined transplant at the first sign of fibrosis; others wait for clinical decompensation. The study demonstrates that combined transplantation is effective 0:48 and increasingly common 0:48, but it does not resolve when to pursue it.

Similarly, the comparison group — heart transplant alone — is not described in detail 0:41. Were those patients screened for liver disease and found not to meet transplant criteria, or were they from an earlier era when combined transplantation was not offered? If the latter, the survival equivalence is less informative, because it compares modern combined transplant outcomes to historical heart-only outcomes in a population whose liver disease may have been underrecognized.

When to Involve This Team

Any Fontan patient being evaluated for heart transplant requires hepatology consultation and cross-sectional liver imaging 0:11 0:11. If there is any laboratory or imaging suggestion of cirrhosis — thrombocytopenia, splenomegaly, varices, nodular liver contour — the evaluation should include a multidisciplinary transplant conference with hepatology, cardiology, and transplant surgery present 0:11. The decision to list for combined transplantation is not made by any single service 0:11.

Referral should happen early 0:11. Fontan patients often decompensate quickly once heart failure progresses, and dual-organ listing requires time to complete the hepatology workup, optimize nutrition, and coordinate with the transplant network 0:11. Waiting until the patient is in cardiogenic shock or hepatic encephalopathy forecloses options. The threshold for referral is lower than it was five years ago, because the data now support combined transplantation as a viable strategy rather than an experimental one 0:48 0:48.